# Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

> **NCT06531018** · PHASE1,PHASE2 · RECRUITING · sponsor: **Renata PLC** · enrollment: 100 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag 25 MG
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT06531018
- **Lead sponsor:** Renata PLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531018, "Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06531018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*